$EUDA

EUDA Health Holdings (NASDAQ: EUDA) said it signed a tri-party memorandum of understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on developing, manufacturing, and commercializing next-generation iPSC-derived off-the-shelf oncology cell therapies. The company framed the deal as advancing its commercialization and distribution strategy.

EUDA Health Holdings (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider focusing on longevity and preventive health in Asia, with operations in Singapore, Malaysia, China, and expanding into India. The company is developing stem cell therapy platforms, launching consumer wellness products like EUDA Helixé, and integrating a digital health and rewards ecosystem using a QB utility token. Additionally, EUDA also manages a property management business in Singapore and utilizes various financing instruments to support its growth.

SINGAPORE, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- EUDA Health Holdings Limited ( NASDAQ: EUDA ) ( "EUDA" or the "Company" ) , a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte.

SINGAPORE, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- EUDA Health Holdings Limited EUDA ( "EUDA" or the "Company" ) , a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent ( the "LOI" ) to ...